NASDAQ:ZYNE

Zynerba Pharmaceuticals - ZYNE Stock Forecast, Price & News

$0.82

+0.09 (+12.25%)

(As of 10/6/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.71
▼
$0.83
50-Day Range: $0.73
▼
$1.36
52-Week Range: $0.71
▼
$4.36

Volume: 563,478 shs
Average Volume: 485,320 shs
Market Capitalization: $37.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.33

Zynerba Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,153.1% Upside
$10.33 Price Target
Short Interest: Healthy
1.75% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.57
Based on 3 Articles This Week
Insider Trading: Selling Shares
$33,530 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.91) to ($0.80) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

312th out of 1,075 stocks

Pharmaceutical Preparations Industry

132nd out of 537 stocks

3.5

Analyst's Opinion

Consensus Rating
Zynerba Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.33, Zynerba Pharmaceuticals has a forecasted upside of 1,153.1% from its current price of $0.82.
Amount of Analyst Coverage
Zynerba Pharmaceuticals has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.75% of the outstanding shares of Zynerba Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Zynerba Pharmaceuticals has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Zynerba Pharmaceuticals has recently increased by 11.16%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Zynerba Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Zynerba Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ZYNE.

3.6

News and Social Media Coverage

News Sentiment
Zynerba Pharmaceuticals has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Zynerba Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
15 people have searched for ZYNE on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
MarketBeat Follows
6 people have added Zynerba Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zynerba Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $33,530.00 in company stock.
Percentage Held by Insiders
10.54% of the stock of Zynerba Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 24.00% of the stock of Zynerba Pharmaceuticals is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Zynerba Pharmaceuticals are expected to grow in the coming year, from ($0.91) to ($0.80) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Zynerba Pharmaceuticals is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zynerba Pharmaceuticals is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Zynerba Pharmaceuticals has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Zynerba Pharmaceuticals (NASDAQ:ZYNE) Stock

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

Receive ZYNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ZYNE Stock News Headlines

October 6, 2022 | proactiveinvestors.com

Zynerba Pharmaceuticals receives new US patent for its cannabidiol formulated gel Zygel

October 6, 2022 | finance.yahoo.com

Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™

October 4, 2022 | marketwatch.com

Pain Management Drugs Market Size, Share 2022 : Industry Growing Rapidly with Recent Trends, Development, Revenue by 2027

September 29, 2022 | finance.yahoo.com

Zynerba Pharmaceuticals to Participate in the Cantor Neurology & Psychiatry Conference

September 22, 2022 | finance.yahoo.com

Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference

September 17, 2022 | finance.yahoo.com

Zynerba Pharmaceuticals, Inc. (ZYNE)

September 8, 2022 | finance.yahoo.com

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium

September 6, 2022 | finance.yahoo.com

Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference

August 31, 2022 | finance.yahoo.com

Zynerba Pharmaceuticals Announces Oral Presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium

August 17, 2022 | nasdaq.com

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

August 16, 2022 | seekingalpha.com

Zynerba Pharmaceuticals (ZYNE) Investor Presentation - Slideshow

August 11, 2022 | proactiveinvestors.com

Zynerba Pharmaceuticals gets renewed 'Buy' rating, premium $11 price target from Canaccord Genuity after growth conference

August 10, 2022 | msn.com

Zynerba Pharmaceuticals R&D Expanses For Q2 Reach 5.4M, Here Are The Details

August 10, 2022 | proactiveinvestors.com

Zynerba Pharmaceuticals reports Q2 results and provides operational update

August 10, 2022 | nz.finance.yahoo.com

Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights

August 3, 2022 | finance.yahoo.com

Zynerba Pharmaceuticals to Present In Person at the Canaccord Genuity 42nd Annual Growth Conference

August 1, 2022 | finance.yahoo.com

We're Hopeful That Zynerba Pharmaceuticals (NASDAQ:ZYNE) Will Use Its Cash Wisely

July 21, 2022 | proactiveinvestors.com

Zynerba Pharmaceuticals increases financial flexibility with $20M equity purchase agreement

July 21, 2022 | proactiveinvestors.com

Zynerba Pharmaceuticals enters into equity purchase agreement for up to $20M with Lincoln Park Capital

July 21, 2022 | finance.yahoo.com

Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital

July 21, 2022 | finance.yahoo.com

Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital

July 7, 2022 | finance.yahoo.com

Zynerba Pharmaceuticals Announces Panel Presentation and Poster Presentations at the NFXF International Fragile X Conference

June 24, 2022 | finance.yahoo.com

Lab Notes: AmerisourceBergen aims to help cell and gene therapy developers, Penn spinout expands research deal with university

June 22, 2022 | finance.yahoo.com

Zynerba's Cannabidiol Formulated Gel Shows Encouraging Action In Genetic Disease

June 22, 2022 | benzinga.com

Zynerba Pharmaceuticals Reveals Positive Results From Phase 2 INSPIRE Trial Of Zygel In 22q11.2 Deletion Syndrome

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ZYNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ZYNE Company Calendar

Last Earnings: 8/10/2022
Today: 10/06/2022
Next Earnings (Estimated): 11/21/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ZYNE
CUSIP: N/A
CIK: 1621443
Web: www.zynerba.com
Phone: (484) 581-7505
Fax: N/A
Employees: 28
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.33
High Stock Price Forecast: $11.00
Low Stock Price Forecast: $9.00
Forecasted Upside/Downside: +1,153.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.93)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-37,310,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -55.50%
Return on Assets: -48.30%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.89
Quick Ratio: 6.89

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.72 per share
Price / Book: 0.48

Miscellaneous

Outstanding Shares: 45,753,000
Free Float: 40,931,000
Market Cap: $37.73 million
Optionable: Optionable
Beta: 1.89

Key Executives

Mr. Armando Anido MBA (Age 64)
Chairman & CEO
Comp: $993.36k

Ms. Terri B. Sebree (Age 64)
Pres
Comp: $764.03k

Mr. James E. Fickenscher (Age 58)
CFO & VP of Corp. Devel.
Comp: $608.02k

Mr. Albert P. Parker II (Age 56)
Chief Legal Officer & Corp. Sec.

Mr. Joseph Apostolico
VP of HR

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ZYNE Stock - Frequently Asked Questions

Should I buy or sell Zynerba Pharmaceuticals stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZYNE shares.
View ZYNE analyst ratings or view top-rated stocks.
What is Zynerba Pharmaceuticals' stock price forecast for 2022?: 3 Wall Street analysts have issued 1 year price objectives for Zynerba Pharmaceuticals' stock. Their ZYNE share price forecasts range from $9.00 to $11.00. On average, they anticipate the company's stock price to reach $10.33 in the next year. This suggests a possible upside of 1,296.6% from the stock's current price.
View analysts price targets for ZYNE or view top-rated stocks among Wall Street analysts.
How have ZYNE shares performed in 2022?: Zynerba Pharmaceuticals' stock was trading at $2.88 at the start of the year. Since then, ZYNE stock has decreased by 74.3% and is now trading at $0.7399.
View the best growth stocks for 2022 here.
When is Zynerba Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our ZYNE earnings forecast.
How were Zynerba Pharmaceuticals' earnings last quarter?: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) released its earnings results on Wednesday, August, 10th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.03.

What other stocks do shareholders of Zynerba Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Shopify (SHOP) and Micron Technology (MU).
When did Zynerba Pharmaceuticals IPO?: (ZYNE) raised $42 million in an initial public offering (IPO) on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.
What is Zynerba Pharmaceuticals' stock symbol?: Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."
How do I buy shares of Zynerba Pharmaceuticals?: Shares of ZYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Zynerba Pharmaceuticals' stock price today?: One share of ZYNE stock can currently be purchased for approximately $0.74.
How much money does Zynerba Pharmaceuticals make?: Zynerba Pharmaceuticals (NASDAQ:ZYNE) has a market capitalization of $33.85 million. The company earns $-37,310,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis.
How can I contact Zynerba Pharmaceuticals?: Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The official website for the company is www.zynerba.com. The company can be reached via phone at (484) 581-7505 or via email at investorrelations@zynerba.com.

This page (NASDAQ:ZYNE) was last updated on 10/6/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Zynerba Pharmaceuticals - ZYNE Stock Forecast, Price & News

Zynerba Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows